Literature DB >> 33925087

AAV-HDV: An Attractive Platform for the In Vivo Study of HDV Biology and the Mechanism of Disease Pathogenesis.

Sheila Maestro1,2, Nahia Gómez-Echarte1,2, Gracián Camps1,2, Carla Usai1,2, Lester Suárez3, África Vales1,2, Cristina Olagüe1,2, Rafael Aldabe1,2, Gloria González-Aseguinolaza1,2.   

Abstract

Hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis, but little is known about the molecular mechanisms involved. We have recently developed an HDV mouse model based on the delivery of HDV replication-competent genomes using adeno-associated vectors (AAV), which developed a liver pathology very similar to the human disease and allowed us to perform mechanistic studies. We have generated different AAV-HDV mutants to eliminate the expression of HDV antigens (HDAgs), and we have characterized them both in vitro and in vivo. We confirmed that S-HDAg is essential for HDV replication and cannot be replaced by L-HDAg or host cellular proteins, and that L-HDAg is essential to produce the HDV infectious particle and inhibits its replication. We have also found that lack of L-HDAg resulted in the increase of S-HDAg expression levels and the exacerbation of liver damage, which was associated with an increment in liver inflammation but did not require T cells. Interestingly, early expression of L-HDAg significantly ameliorated the liver damage induced by the mutant expressing only S-HDAg. In summary, the use of AAV-HDV represents a very attractive platform to interrogate in vivo the role of viral components in the HDV life cycle and to better understand the mechanism of HDV-induced liver pathology.

Entities:  

Keywords:  AAV; HDAg; HDV; liver damage; mouse model

Year:  2021        PMID: 33925087     DOI: 10.3390/v13050788

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  42 in total

1.  Development of a novel system to study hepatitis delta virus genome replication.

Authors:  Jinhong Chang; Severin O Gudima; Chi Tarn; Xingcao Nie; John M Taylor
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.

Authors:  Lester Suárez-Amarán; Carla Usai; Marianna Di Scala; Cristina Godoy; Yi Ni; Mirja Hommel; Laura Palomo; Víctor Segura; Cristina Olagüe; Africa Vales; Alicia Ruiz-Ripa; Maria Buti; Eduardo Salido; Jesús Prieto; Stephan Urban; Francisco Rodríguez-Frias; Rafael Aldabe; Gloria González-Aseguinolaza
Journal:  J Hepatol       Date:  2017-05-18       Impact factor: 25.083

3.  A novel chromosome region maintenance 1-independent nuclear export signal of the large form of hepatitis delta antigen that is required for the viral assembly.

Authors:  C H Lee; S C Chang; C H Wu; M F Chang
Journal:  J Biol Chem       Date:  2000-11-13       Impact factor: 5.157

4.  Hepatitis delta virus RNA, protein synthesis and associated cytotoxicity in a stably transfected cell line.

Authors:  T B Macnaughton; E J Gowans; A R Jilbert; C J Burrell
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

5.  Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.

Authors:  Yi Ni; Florian A Lempp; Stefan Mehrle; Shirin Nkongolo; Christina Kaufman; Maria Fälth; Jan Stindt; Christian Königer; Michael Nassal; Ralf Kubitz; Holger Sültmann; Stephan Urban
Journal:  Gastroenterology       Date:  2013-12-19       Impact factor: 22.682

Review 6.  Bulevirtide: First Approval.

Authors:  Connie Kang; Yahiya Y Syed
Journal:  Drugs       Date:  2020-10       Impact factor: 9.546

7.  Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.

Authors:  Wenhui He; Bijie Ren; Fengfeng Mao; Zhiyi Jing; Yunfei Li; Yang Liu; Bo Peng; Huan Yan; Yonghe Qi; Yinyan Sun; Ju-Tao Guo; Jianhua Sui; Fengchao Wang; Wenhui Li
Journal:  PLoS Pathog       Date:  2015-04-22       Impact factor: 6.823

8.  Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection.

Authors:  Zhijiang Miao; Shaoshi Zhang; Xumin Ou; Shan Li; Zhongren Ma; Wenshi Wang; Maikel P Peppelenbosch; Jiaye Liu; Qiuwei Pan
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

9.  Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes.

Authors:  Habiba Kamal; Gabriel Westman; Karolin Falconer; Ann-Sofi Duberg; Ola Weiland; Susanna Haverinen; Rune Wejstål; Tony Carlsson; Christian Kampmann; Simon B Larsson; Per Björkman; Anders Nystedt; Kristina Cardell; Stefan Svensson; Stephan Stenmark; Heiner Wedemeyer; Soo Aleman
Journal:  Hepatology       Date:  2020-09-24       Impact factor: 17.425

10.  Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection.

Authors:  Maria Homs; Francisco Rodriguez-Frias; Josep Gregori; Alicia Ruiz; Pilar Reimundo; Rosario Casillas; David Tabernero; Cristina Godoy; Salma Barakat; Josep Quer; Mar Riveiro-Barciela; Michael Roggendorf; Rafael Esteban; Maria Buti
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

View more
  1 in total

Review 1.  Adaptive Immune Responses, Immune Escape and Immune-Mediated Pathogenesis during HDV Infection.

Authors:  Valerie Oberhardt; Maike Hofmann; Robert Thimme; Christoph Neumann-Haefelin
Journal:  Viruses       Date:  2022-01-20       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.